These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33594487)

  • 21. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Jung C; Park S; Kim H
    PLoS One; 2023; 18(11):e0294423. PubMed ID: 37992029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
    Fu AZ; Johnston SS; Ghannam A; Tsai K; Cappell K; Fowler R; Riehle E; Cole AL; Kalsekar I; Sheehan J
    Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study.
    Pradhan R; Yu OHY; Platt RW; Azoulay L
    BMJ Open Diabetes Res Care; 2023 Nov; 11(6):. PubMed ID: 37949470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between dipeptidyl peptidase-4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study.
    Imatoh T; Nishi T; Yasui M; Maeda T; Sai K; Saito Y; Une H; Babazono A
    Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):931-939. PubMed ID: 29851174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
    Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
    J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH; Kim B; Choi H; Kim DJ; Kim HC
    Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
    Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
    Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
    Toh S; Hampp C; Reichman ME; Graham DJ; Balakrishnan S; Pucino F; Hamilton J; Lendle S; Iyer A; Rucker M; Pimentel M; Nathwani N; Griffin MR; Brown NJ; Fireman BH
    Ann Intern Med; 2016 Jun; 164(11):705-14. PubMed ID: 27110660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
    Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
    Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
    Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
    BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
    Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
    Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis.
    Kim MK; Han K; Kwon HS; Yoo SJ
    Endocrinol Metab (Seoul); 2023 Aug; 38(4):426-435. PubMed ID: 37469033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB; Tang X; Han M; Yang J; Simó R
    Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
    Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
    J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus.
    Ock M; Lee S; Kim H
    J Clin Pharm Ther; 2022 Jul; 47(7):1028-1035. PubMed ID: 35257383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
    Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
    Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.